tiprankstipranks
Advertisement
Advertisement

ZBIO Stock Latest News

Zenas BioPharma Raises Capital via Notes and Equity Offering
Company AnnouncementsZenas BioPharma Raises Capital via Notes and Equity Offering
5d ago
8K
ZBIO
Zenas BioPharma director buys $1.5M in common stock
PremiumThe Fly
Zenas BioPharma director buys $1.5M in common stock
5d ago
ZBIO
Zenas BioPharma 5M share Spot Secondary priced at $20.00
PremiumThe Fly
Zenas BioPharma 5M share Spot Secondary priced at $20.00
9d ago
ZBIO
Closing Bell Movers: Argan jumps 10% on earnings beat
PremiumThe Fly
Closing Bell Movers: Argan jumps 10% on earnings beat
10d ago
U
AGX
Zenas announces common stock, convertible senior notes offerings
PremiumThe Fly
Zenas announces common stock, convertible senior notes offerings
10d ago
ZBIO
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
PremiumCompany AnnouncementsZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
16d ago
ZBIO
Zenas BioPharma price target raised to $55 from $45 at Guggenheim
Premium
The Fly
Zenas BioPharma price target raised to $55 from $45 at Guggenheim
19d ago
ZBIO
Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
Premium
Ratings
Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
19d ago
ZBIO
Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
PremiumThe Fly
Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
19d ago
ZBIO
Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
PremiumRatings
Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
19d ago
ZBIO
Zenas BioPharma price target lowered to $41 from $43 at Citi
PremiumThe Fly
Zenas BioPharma price target lowered to $41 from $43 at Citi
19d ago
ZBIO
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
PremiumCompany Announcements
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
20d ago
ZBIO
Morning Movers: National Storage surges following Public Storage buyout
PremiumThe FlyMorning Movers: National Storage surges following Public Storage buyout
20d ago
MU
WW
Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year
Premium
The Fly
Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year
20d ago
ZBIO
Zenas BioPharma sees cash runway into 4Q27
Premium
The Fly
Zenas BioPharma sees cash runway into 4Q27
20d ago
ZBIO
Zenas BioPharma added to Best Ideas List at Wedbush
PremiumThe Fly
Zenas BioPharma added to Best Ideas List at Wedbush
2M ago
ZBIO
Zenas BioPharma Adopts Amended Short-Term Incentive Plan
PremiumCompany Announcements
Zenas BioPharma Adopts Amended Short-Term Incentive Plan
2M ago
8K
ZBIO
Zenas BioPharma: Advancing Autoimmune Pipeline and Obexelimab’s Differentiated MS Profile Support Buy Rating and $44 Target
PremiumRatings
Zenas BioPharma: Advancing Autoimmune Pipeline and Obexelimab’s Differentiated MS Profile Support Buy Rating and $44 Target
2M ago
ZBIO
Zenas BioPharma says obexelimab met primary endpoint in Phase 2 study
PremiumThe Fly
Zenas BioPharma says obexelimab met primary endpoint in Phase 2 study
2M ago
ZBIO
3 Stocks with a ‘Perfect 10’ Smart Score
PremiumMarket News3 Stocks with a ‘Perfect 10’ Smart Score
3M ago
DAWN
GLOO
Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley
3M ago
ZBIO
Citi trims Zenas BioPharma target, calls pullback on INDIGO an ‘overreaction’
Premium
The Fly
Citi trims Zenas BioPharma target, calls pullback on INDIGO an ‘overreaction’
3M ago
ZBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >